Metabolism of Omega-3 and Omega-6 During Healthy Aging
Metabolism of Uniformly Labelled 13C Eicosapentaenoic Acid and 13C Arachidonic Acid During Healthy Aging
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- six young (18-30 y old) and six older (≥ 70 y old)
- healthy non medicated participants.
Exclusion Criteria:
- Tobacco,
- malnutrition (assessed from blood albumin, haemoglobin and lipids), -
- participants taking an EPA+DHA supplements or consuming more than 2 fish meals per week,
- severe gastro-intestinal problems,
- medication for diabetes,
- thyroid disease,
- renal failure,
- cancer,
- psychiatric difficulties or depression,
- cardiovascular disease,
- glucose intolerance (>8 mmol/L in fasted samples)
- chronic immune condition or inflammation (CRP > 10 mg/l, white cell count),
- recent major surgery or cardiac event,
- dementia,
- ongoing or past severe drug or alcohol abuse,
- ongoing or past intensive physical training.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Young
Six young (18-30 yrs old) healthy participants were recruited.
The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up.
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
|
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
|
|
Elderly
Six older (≥ 70 yrs old) healthy participants were recruited.
The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up.
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
|
Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Kinetics of 13C-EPA and 13C-AA
Time Frame: Plasma incorporation of 13C-EPA or 13C-AA was measured from the area under the curve in young and older participants over 28 days post-dose
|
Plasma incorporation of 13C-EPA or 13C-AA was measured from the area under the curve in young and older participants over 28 days post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 13C EPA and 13C AA metabolism
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.